Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | PDGFRB |
Variant | over exp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | PDGFRB over exp indicates an over expression of the Pdgfrb protein. However, the mechanism causing the over expression is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PDGFRB over exp | melanoma | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and overexpressing Pdgfrb demonstrated resistance to Mekinist (trametinib) in culture (PMID: 28986383). | 28986383 |
BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and overexpressing Pdgfrb demonstrated resistance to Zelboraf (vemurafenib) in culture (PMID: 28986383). | 28986383 |
BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical | Actionable | In a preclinical study, over expression of PDGFRB conferred acquired resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323). | 21107323 |
BRAF V600E PDGFRB over exp | melanoma | sensitive | XL888 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with XL888 increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant human melanoma cell lines harboring a BRAF V600E mutation and over expression of PDGFRB in cell culture and in xenograft models (PMID: 22351686). | 22351686 |
BRAF mut PDGFRB over exp | melanoma | predicted - sensitive | BI-847325 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to PDGFRB over expression in culture (PMID: 25873592). | 25873592 |
KIT neg PDGFRB over exp | breast cancer | no benefit | Imatinib | Phase II | Actionable | In a Phase II trial, Gleevec (imatinib mesylate) treatment demonstrated no clinical activity, resulted in no objective response (0/13) in patients with metastatic breast cancer demonstrating Pdgfrb overexpression and negative Kit expression (PMID: 18515258). | 18515258 |